A tankyrase inhibitor impairs tumor growth and angiogenesis through the Wnt/B-catenin attenuation

GRISELDA IRUSTA; MARTA TESONE; BOCCHICCHIO, SEBASTIAN

Buenos Aires

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

Aberrant regulation of Wnt signaling pathway is a prevalent theme in cancer biology. While it has been demonstrated to be involved in many types of tumours it has been poorly studied in ovarian cancer. We analyzed the effect of inhibiting Wnt/β-catenin in a xenograft model of human ovarian cancer. A human ovarian adenocarcinoma cell line (IGROV-1) was subcutaneously injected in 6-8 weeks-old female nude mice. Once the tumour was palpable, we injected a tankyrase inhibitor, which attenuates Wnt/β-catenin signalling (XAV939: 2.5 and 5 mg/kg) every two days three times. Mice were euthanized 3 days after the last injection. The involvement of Wnt/β-catenin pathway in tumour growth, morphology and angiogenesis was evaluated. Our results showed a significant decrease in tumour size when mice were treated with XAV939, which strikingly, was higher at the 2.5 mg/kg dose than the 5 mg/kg dose (day 7: no treated animals vs. 2.5 mg/kg group, p